Gyre Therapeutics

GYRE

Biotechnology · Healthcare

Price

$6.91

-0.11 (-1.57%)

Market Cap

$770.4M

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Dividends

Good

Track this stock — start free trial

Share count rising — dilution

+236.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 30.6M (2021) → 103.2M (2025)

Winston Score History

The full picture

Gyre Therapeutics is a biopharmaceutical company focused on developing and selling drugs that treat fibrotic diseases — conditions where organs like the liver or lungs develop harmful scar tissue. Its lead product, Hydronidone, targets liver fibrosis, and the company primarily serves patients and healthcare providers in China, where it operates through its subsidiary. Gyre sits within the specialty drug space, targeting a large and underserved patient population with few approved treatment options.

The company earns revenue mainly through drug sales in China, which explains its high gross margin — a common feature of pharmaceutical businesses once a drug reaches market. Gyre is relatively small, with a market cap around $800 million, and its competitive position depends heavily on regulatory approvals and its pipeline in a market where local Chinese biotech firms also compete. The key risk is that the company is currently operating at a loss, meaning it must successfully advance its pipeline and grow sales volume before it can achieve sustainable profitability.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-2.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$14M/ year

↑ Rising (+14% vs prior year)

11.7% of revenue

Below sector average (18%)

Investing heavily in future products and technology

Insider Activity

70.5%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~12 months

$75M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Gyre Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

92.4%

Premium pricing power — 92.4% gross margin

Profit after running costs

Operating Margin

-49.3%

Losing money on operations — -49.3%

Return on the money invested

ROCE

-12.8%

Weak — -12.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+13.5%

Fast-growing sales (+13.5% YoY)

Profit growth

EPS YoY

-524.1%

Earnings shrinking (-524.1% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-14.1%

Burning cash (-14.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

13.89%

Healthy income — 13.89% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record

Dividend Growth

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial